Familial Cancer

, Volume 9, Issue 3, pp 449–457 | Cite as

Update multiple endocrine neoplasia type 2

  • Friedhelm RaueEmail author
  • Karin Frank-Raue


Multiple endocrine neoplasia type 2 (MEN2) is a autosomal dominat inherited tumour-syndrome caused by germline activating mutations of the RET proto-oncogene on chromosome 10. It is clinically characterized by the presence of medullary thyroid carcinoma (MTC), bilateral pheochromocytoma and primary hyperparathyroidism (MEN2A) within a single patient. Three distinct clinical forms have been described depending on the phenotype: the classical MEN 2A, MEN 2B, an association of MTC, pheochromocytoma and mucosal neuroma, (FMTC) familial MTC with a low incidence of other endocrinopathies. Each variant of MEN2 results from different RET gene mutation, with a good genotype phenotype correlation. Genetic testing detects nearly 100% of mutation carriers and is considered the standard of care for all first degree relatives of patients with newly diagnosed MTC. Recommendations on the timing of prophylactic thyroidectomy and extent of surgery are based on a classification into four risk levels utilizing the genotype-phenotype correlations. MEN 2 gives a unique model for early prevention and cure of cancer and for stratified roles of mutation-based diagnosis of carriers.


Multiple endocrine neoplasia type 2 Pheochromocytoma Primary hyperparathyroidism Ganglioneuromarosis RET proto-oncogene Tyrosine kinase inhibitors 



Multiple endocrine neoplasia


Medullary thyroid carcinoma






Primary hyperparathyroidism


Familial medullary thyroid carcinoma

RET gene

Rearranged during transfection gene


C-cell hyperplasia


  1. 1.
    Mulligan LM, Kwok JBJ, Healey CS et al (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2a (MEN 2A). Nature 363:458–469CrossRefPubMedGoogle Scholar
  2. 2.
    Donis-Keller H, Dou S, Chi D et al (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genetics 2:851–856CrossRefGoogle Scholar
  3. 3.
    Raue F, Frank-Raue K, Grauer A (1994) Multiple endocrine neoplasia type 2, clinical features and screening. Endocrin Metab Clin North Am 23:137–156Google Scholar
  4. 4.
    Brandi ML, Gagel R, Angeli A et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658–5671CrossRefPubMedGoogle Scholar
  5. 5.
    Vasen HF, van der Feltz M, Raue F et al (1992) The natural course of multiple endocrine neoplasia type 2 b. Arch Intern Med 152:1250–1252CrossRefPubMedGoogle Scholar
  6. 6.
    Berndt I, Reuter M, Saller B et al (1998) A new hotspot for mutations in the RET proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83:770–774CrossRefPubMedGoogle Scholar
  7. 7.
    Kloos RT, Eng C, Evans DB et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565–612CrossRefPubMedGoogle Scholar
  8. 8.
    Brauckhoff M, Machens A, Hess S et al (2008) Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis. Surgery 144:1044–1051CrossRefPubMedGoogle Scholar
  9. 9.
    Eng C, Mulligan LM, Smith DP et al (1995) Low frequency of germline mutations in the RET protooncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol 43:123–127CrossRefGoogle Scholar
  10. 10.
    Machens A, Niccoli-Sire P, Hoegel J et al (2003) Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517–1525CrossRefPubMedGoogle Scholar
  11. 11.
    LiVolsi VA (1997) C cell hyperplasia/neoplasia. J Clin Endocrinol Metab 82:39–41CrossRefPubMedGoogle Scholar
  12. 12.
    Grauer A, Raue F, Ziegler R (1998) Clinical usefullness of a new chemoluminescent two-site immunoassy for human calcitonin. Exp Clin Endorcinol Diabetes 106:353–359CrossRefGoogle Scholar
  13. 13.
    Cohen R, Campos JM, Salaün C et al (2000) Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. J Clin Endocrinol Metab 85:905–918CrossRefGoogle Scholar
  14. 14.
    Mathew CG, Chin KS, Easton DF et al (1987) A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328:527–528CrossRefPubMedGoogle Scholar
  15. 15.
    Romei C, Elisei R, Pinchera A et al (1996) Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 81:1619–1622CrossRefPubMedGoogle Scholar
  16. 16.
    Elisei R, Cosci B, Romei C et al (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93:682–687CrossRefPubMedGoogle Scholar
  17. 17.
    Mulligan LM, Marsh DJ, Robinson BG et al (1995) Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Int Med 238:343–346CrossRefGoogle Scholar
  18. 18.
    Eng C, Clayton D, Schuffenecker I et al (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium analysis. JAMA 276:1575–1579CrossRefPubMedGoogle Scholar
  19. 19.
    Frank-Raue K, Höppner W, Frilling A et al (1996) Mutations of the RET proto-oncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. J Clin Endocrinol Metab 81:1780–1783CrossRefPubMedGoogle Scholar
  20. 20.
    Machens A, Brauckhoff M, Holzhausen HJ et al (2005) Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 90:3999–4003CrossRefPubMedGoogle Scholar
  21. 21.
    Quayle FJ, Fialkowski EA, Benveniste R et al (2007) Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery 142:800–805CrossRefPubMedGoogle Scholar
  22. 22.
    Schuffenecker I, Virally-Monod M, Brohet R et al (1998) Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. J Clin Endocrinol Metab 83:487–491CrossRefPubMedGoogle Scholar
  23. 23.
    Kouvaraki MA, Shapiro SE, Perrier ND et al (2005) RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15:531–544CrossRefPubMedGoogle Scholar
  24. 24.
    Frank-Raue K, Rondot S, Schulze E et al (2007) Change in the spectrum of RET mutations diagnosed between 1994 and 2006. Clin Lab 53:273–282PubMedGoogle Scholar
  25. 25.
    Moers AM, Lansvater RM, Schaap C et al (1996) Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family. Am J Med 101:635–641CrossRefPubMedGoogle Scholar
  26. 26.
    Bolino A, Schuffenecker I, Luo Y et al (1995) RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10:2415–2419PubMedGoogle Scholar
  27. 27.
    Smith DP, Houghton C, Ponder BA (1995) Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 15:1213–1217CrossRefGoogle Scholar
  28. 28.
    Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803CrossRefPubMedGoogle Scholar
  29. 29.
    Neumann HP, Bausch B, McWhinney SR et al (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459–1466CrossRefPubMedGoogle Scholar
  30. 30.
    Frank-Raue K, Machens A, Scheuba C et al (2008) Difference in the development of medullary thyroid carcinoma among carriers of RET mutations in codon 790 and 791. Clin Endocrinol 69:259–263CrossRefGoogle Scholar
  31. 31.
    Frank-Raue K, Buhr H, Dralle H et al (2006) Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol 155:229–236CrossRefPubMedGoogle Scholar
  32. 32.
    Moley JF, Fialkowski EA (2007) Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 31:946–956CrossRefPubMedGoogle Scholar
  33. 33.
    Giraudet AL, Al Ghulzan A, Auperin A et al (2008) Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158:239–246CrossRefGoogle Scholar
  34. 34.
    Ball DW (2007) Medullary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin N Am 36:823–837CrossRefGoogle Scholar
  35. 35.
    Sherman SI (2009) Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 94:1493–1499CrossRefPubMedGoogle Scholar
  36. 36.
    Raue F (1998) German medullary thyroid carcinoma/multiple endocrine neoplasia registry. Langenbeck‘s Arch Surg 383:334–336CrossRefGoogle Scholar
  37. 37.
    Kebebew E, Ituarte PHG, Siperstein AE et al (2000) Medullary thyroid carcinoma, clinical characteristics, treatment, prognostic factors and a comparison of staging systems. Cancer 88:1139–1148CrossRefPubMedGoogle Scholar
  38. 38.
    Roman S, Lin R, Sosa JA (2006) Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathological predictors of survival in 1252 cases. Cancer 107:2134–2142CrossRefPubMedGoogle Scholar
  39. 39.
    de Groot JW, Plukker JTM, Wolffenbuttel BHR (2006) Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol 65:729–736CrossRefGoogle Scholar
  40. 40.
    Bergholm U, Bergstrom R, Ekbom A (1997) Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer 79:132–138CrossRefPubMedGoogle Scholar
  41. 41.
    Skinner MA, Moley JA, Dilley WG et al (2005) Prophylactic thyroidectomy in multiple endocrine neoplasia type 2. N Engl J Med 353:1105–1113CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  1. 1.Endocrine PracticeHeidelbergGermany
  2. 2.Endokrinologische GemeinschaftspraxisHeidelbergGermany

Personalised recommendations